22.78

1.09% -0.25

Monte Rosa Therapeutics Inc (GLUE)

Overview News Price History Option Chain Financials Why GLUE Down? Discussions Forecast

Monte Rosa Therapeutics Inc stock is traded at $22.78, with a volume of 868.79K. It is down -1.09% in the last 24 hours and up +9.26% over the past month. Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Previous Close:

$23.03

Open:

$23.27

24h Volume:

868.79K

Relative Volume:

0.77

Market Cap:

$1.92B

Revenue:

$42.95M

Net Income/Loss:

$-130.01M

P/E Ratio:

-13.99

EPS:

-1.6278

Net Cash Flow:

$-19.66M

1W Performance:

-7.25%

1M Performance:

+9.26%

6M Performance:

-0.26%

1Y Performance:

+298.95%

1-Day Range:

$22.37

$24.17

1-Week Range:

$22.37

$25.16

52-Week Range:

$4.12

$25.77

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name

Monte Rosa Therapeutics Inc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

617-949-2643

Address

321 HARRISON AVENUE, BOSTON

Employee

161

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

GLUE's Discussions on Twitter

Compare GLUE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GLUE Monte Rosa Therapeutics Inc	22.78	1.92B	42.95M	-130.01M	-19.66M	-1.6278
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Feb-15-24	Initiated	Wedbush	Outperform
Jan-03-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-13-22	Initiated	UBS	Buy
Aug-15-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Credit Suisse	Neutral
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Oct-14-21	Initiated	SVB Leerink	Mkt Perform

View All

Monte Rosa Therapeutics Inc Stock (GLUE) Latest News

Jul 24, 2026

Price to sales forward of Monte Rosa Therapeutics, Inc. – BOATS:GLUE - TradingView

Jul 24, 2026

Allspring Global Investments Holdings LLC Buys 365,272 Shares of Monte Rosa Therapeutics, Inc. $GLUE - MarketBeat

Jul 24, 2026

Jul 23, 2026

Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - The Manila Times

Jul 23, 2026

Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsight - GlobeNewswire Inc.

Jul 23, 2026

Jul 20, 2026

Enterprise value to EBITDA forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView

Jul 20, 2026

Have Insiders Sold Monte Rosa Therapeutics Shares Recently? - simplywall.st

Jul 20, 2026

Jul 19, 2026

Enterprise value to revenue forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView

Jul 19, 2026

Price to earnings forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView

Jul 19, 2026

Jul 17, 2026

Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeutics Inc (GLUE) - GuruFocus

Jul 17, 2026

Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus

Jul 17, 2026

Monte Rosa Therapeutics CEO Markus Warmuth Disposes of Nearly 9,500 Shares at $23.18 Average Price - Kalkine Media

Jul 17, 2026

Monte Rosa Therapeutics (GLUE) CEO sells 9,500 shares at about $23 each - Stock Titan

Jul 17, 2026

Monte Rosa CEO Markus Warmuth sells 9,500 shares worth $220,219.55 - Bitget

Jul 17, 2026

Form 144 MONTE ROSA THERAPEUTICS For: 16 July By Investing.com - Investing.com Nigeria

Jul 17, 2026

Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock - Investing.com UK

Jul 17, 2026

Jul 16, 2026

Price to book forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView

Jul 16, 2026

Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates - MSN

Jul 16, 2026

Monte Rosa: COO Jennifer Champoux sells $101,729 of common stock By Investing.com - Investing.com Nigeria

Jul 16, 2026

Form 4 Monte Rosa Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria

Jul 16, 2026

Monte Rosa Therapeutics COO Jennifer Champoux Completes Stock Sales, Option Exercise, and New Grant Under Pre-Arranged Rule 10b5-1 Plan - Kalkine Media

Jul 16, 2026

Monte Rosa Therapeutics (GLUE) COO trades 4,351 shares via option exercise - Stock Titan

Jul 16, 2026

GLUE (NASDAQ: GLUE) holder to sell 9,500 shares under Rule 144 - Stock Titan

Jul 16, 2026

Enterprise value to EBIT forward of Monte Rosa Therapeutics, Inc. – NASDAQ:GLUE - TradingView

Jul 16, 2026